Editorially independent content, supported with advertising
07.19.24
Patients with DME in DRCR Retina Network Protocol AC were switched from bevacizumab to aflibercept if they met specific switch criteria. Where there any baseline factors that predicted a switch? Moderator Rebecca Soares, MD, sits down with panelists Matt Starr, MD, and Nikisha Kothari, MD, to review this study, ask whether the findings are clinically relevant, and explore other risk factors that may be worthy of further investigation.
07.18.25
Diabetic Retinopathy Severity and Income StatusBen Young, MD; Phoebe Mellen, MD; and Jordan Deaner, MD
06.20.25
Photobiomodulation for Age-related Macular DegenerationModerator Barton Blackorby, MD; Hong-Uyen Hua, MD; and Louis Cai, MD
03.21.25
Rates of Ocular AEs After Faricimab InjectionMaura Di Nicola, MD; Sruthi Arepalli, MD; and Barton Blackorby, MD
12.19.24
Switching from Aflibercept to Faricimab in Wet AMD PatientsBen Young, MD, MS; Lediana Goduni, MD; and Joshua Uhr, MD,
11.21.24
New Retina Radio Journal Club w/ VBS: Does Metformin Reduce AMD Risk?Moderator Rebecca Soares, MD; Matt Starr, MD; and Nikisha Kothari, MD
10.17.24
New Retina Radio Journal Club with VBS: Pre-treatment with Chlorhexidine vs. Povidone-Iodine in Endophthalmitis PreventionMaura Di Nicola, MD; Sruthi Arepalli, MD; and Barton Blackorby, MD
09.17.24
New Retina Radio Journal Club w/ VBS: Risk of Death, Stroke, and MI After RAOKatherine Talcott, MD; Kyle Kovacs, MD; and Phoebe Mellen, MD
08.29.24
New Retina Radio Journal Club with VBS: Switching to Faricimab in Wet AMD Patients With a History of Anti-VEGF TherapyBen Young, MD, MS; Lediana Goduni, MD; and Josh Uhr, MD,
07.19.24
New Retina Radio Journal Club w/ VBS: Risk Factors for Switching from Bevacizumab to Aflibercept in Protocol ACRebecca Soares, MD; Matt Starr, MD; and Nikisha Kothari, MD
Show More